DNMT3A and TET2 may be somatically mutated in MDS and AML, suggesting that the acquisition of these mutations is part of a common pathway in the development of both diseases; in these cases, it may be the specific subsequent mutations that determine whether a patient develops MDS or AML. This evidence concerns the gene DNMT3A and acute myeloid leukemia.